Minneapolis-based biotech startup Foxo Technologies went public Friday morning after completing its merger with Texas-based Delwinds Insurance Acquisition Corp.
Foxo started trading under the ticker symbol FOXO, marking the first public debut for a Minnesota company this year.
Delwinds is a special purpose acquisition company (SPAC), a blank check firm created solely to a acquire or merge with an active business.
There have been far fewer new public listings in 2022 relative to last year due to the unsettled economic environment.
The number of initial public offerings, or IPOs, is down 78.6% this year compared to the same time a year ago, according to Connecticut-based Renaissance Capital.
The market for biotech companies has been particularly challenging.
"Overall, the market is in rough shape, and it has been incredibly difficult for biotech and growth companies," Foxo CEO Jon Sabes said in an email. "That said, we are confident that the future of mortality prediction, along with health and wellness assessment, resides in molecular biomarkers."
The stock opened at $9.15 per share on Friday. It closed at $4.05 per share, down 56%, for the day. Markets were down broadly Friday.